Business
Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India
The Company’s global patent portfolio includes granted patents in the United States, Europe, India, Australia, China and Hong Kong, and numerous pending
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":"\nThe Company’s global patent portfolio includes granted patents in the United States, Europe, India, Australia, China and Hong Kong, and numerous pending patents worldwide\n\n\n CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a pioneering AI-driven precision cardiovascular medicine company, today announced that India’s Patent Office has granted a patent to the University of Iowa Research Foundation (“UIRF”) under patent number 484488, titled “A Kit for Determining Methylation Status of a CpG Dinucleotide and a Genotype of a Single Nucleotide Polymorphism.”\n\n\nThe patent was exclusively licensed to the Company from the University of Iowa Research Foundation (UIRF). It was co-invented by Cardio Diagnostics’ founders, Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D., the Chief Executive Officer and Chief Medical Officer of the Company, respectively.\n\n\nHeart Disease in India Begins Earlier in Adults\nThe burden of heart disease in India is substantial and growing, driven by high prevalence rates, significant risk factors, high mortality, and lack of access to specialty cardiology settings. Particularly concerning is the early onset of cardiovascular disease in Indians compared to their western counterparts; Indians are found to develop cardiovascular disease 10-years earlier and during their prime work years. Based on the age at which many Indians are struck with heart disease, the World Economic Forum and Harvard School of Public Health estimate that India’s economic losses related to cardiovascular disease will exceed $2.5 trillion.\n\n\nBy partnering with Indian business leaders to introduce innovative precision-based cardiovascular diagnostic methods and advanced management insights, the Company can help accelerate preventive health initiatives and improve cardiovascular health outcomes in India. This presents a significant opportunity for Cardio Diagnostics to expand its footprint in the world’s fastest growing nation by population.\n\n\nExpanding Access to Scalable Heart Disease Solutions in India\nCardio Diagnostics recently entered into a Supply and Distribution Agreement with Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932 with 14 sales and services offices across India. Aimil is a leader in introducing innovative, best-in-class technologies ...